H. Bernhard

1.9k total citations
35 papers, 1.5k citations indexed

About

H. Bernhard is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, H. Bernhard has authored 35 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in H. Bernhard's work include Immunotherapy and Immune Responses (12 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). H. Bernhard is often cited by papers focused on Immunotherapy and Immune Responses (12 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). H. Bernhard collaborates with scholars based in Germany, United States and Austria. H. Bernhard's co-authors include ML Disis, JR Gralow, Steven Gillis, Alexander Knuth, Barbara Seliger, Christian G. Huber, Julie R. Gralow, Susan L. Hand, Robert Tampé and Martin A. Cheever and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

H. Bernhard

35 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Bernhard Germany 19 876 669 459 266 255 35 1.5k
Clemens B. Caspar Switzerland 13 885 1.0× 736 1.1× 377 0.8× 222 0.8× 297 1.2× 38 1.5k
Elizabeth K. Wansley United States 12 1.0k 1.2× 1.3k 1.9× 235 0.5× 317 1.2× 201 0.8× 15 1.8k
Satoko Matsueda Japan 24 1.2k 1.4× 935 1.4× 713 1.6× 182 0.7× 138 0.5× 85 1.8k
Laurence Lespagnard Belgium 18 934 1.1× 669 1.0× 390 0.8× 130 0.5× 200 0.8× 42 1.8k
A C Bloem Netherlands 18 532 0.6× 363 0.5× 517 1.1× 98 0.4× 132 0.5× 34 1.4k
Anja Dankof Germany 15 348 0.4× 267 0.4× 480 1.0× 160 0.6× 110 0.4× 26 1.3k
Marna Williams United States 15 897 1.0× 529 0.8× 249 0.5× 67 0.3× 271 1.1× 21 1.6k
G A Niehans United States 15 574 0.7× 835 1.2× 1.2k 2.6× 379 1.4× 278 1.1× 15 2.1k
Baldev Vasir United States 20 931 1.1× 762 1.1× 735 1.6× 62 0.2× 145 0.6× 42 1.7k
Nacilla Haicheur France 15 821 0.9× 799 1.2× 279 0.6× 129 0.5× 49 0.2× 25 1.4k

Countries citing papers authored by H. Bernhard

Since Specialization
Citations

This map shows the geographic impact of H. Bernhard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Bernhard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Bernhard more than expected).

Fields of papers citing papers by H. Bernhard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Bernhard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Bernhard. The network helps show where H. Bernhard may publish in the future.

Co-authorship network of co-authors of H. Bernhard

This figure shows the co-authorship network connecting the top 25 collaborators of H. Bernhard. A scholar is included among the top collaborators of H. Bernhard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Bernhard. H. Bernhard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schadendorf, Dirk & H. Bernhard. (2014). Medikamentöse Systemtherapie des Melanoms. Der Onkologe. 20(6). 568–576. 2 indexed citations
2.
Atmaca, Akin, S-E. Al-Batran, Dominique Werner, et al.. (2013). A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. British Journal of Cancer. 108(2). 265–270. 27 indexed citations
3.
Thiel, Uwe, Heinke Conrad, Dirk H. Busch, et al.. (2011). Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells. British Journal of Cancer. 104(6). 948–956. 29 indexed citations
4.
Witter, K., Heinke Conrad, H. Bernhard, Thomas Albert, & Teresa Kauke. (2009). HLA‐B*1832, a novel B allele was found through high‐resolution HLA typing of a Spanish blood donor. Tissue Antigens. 74(2). 170–172. 2 indexed citations
5.
Link, Hartmut, C.-H. Köhne, Michael Stahl, et al.. (2008). Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. British Journal of Cancer. 100(1). 44–49. 55 indexed citations
6.
Bernhard, H., Ulrich Frommberger, Karin Weber, et al.. (2008). Chronifizierte paranoid-halluzinatorische Psychose als Erstmanifestation einer HIV-Infektion?. DMW - Deutsche Medizinische Wochenschrift. 114(13). 503–506. 1 indexed citations
7.
Stemmler, Hans‐Joachim, et al.. (2006). Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncology Reports. 15(5). 1373–7. 65 indexed citations
8.
Lordick, Florian, C. von Schilling, H. Bernhard, et al.. (2003). Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. British Journal of Cancer. 89(4). 630–633. 57 indexed citations
9.
Bernhard, H., Lupe G. Salazar, K Schiffman, et al.. (2002). Vaccination against the HER-2/neu oncogenic protein.. Endocrine Related Cancer. 9(1). 33–44. 43 indexed citations
10.
Disis, ML, et al.. (1996). Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. The Journal of Immunology. 156(9). 3151–3158. 158 indexed citations
11.
Disis, ML, et al.. (1996). Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood. 88(1). 202–210. 260 indexed citations
12.
13.
14.
Bernhard, H., Elke Jäger, Markus Maeurer, K. H. Meyer zum Büschenfelde, & Alexander Knuth. (1996). Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes. Tissue Antigens. 48(1). 22–31. 9 indexed citations
15.
Bernhard, H., Markus Maeurer, Elke Jäger, et al.. (1996). Recognition of Human Renal Cell Carcinoma and Melanoma by HLA‐A2‐Restricted Cytotoxic T Lymphocytes is Mediated by Shared Peptide Epitopes and Up‐Regulated by Interferon‐γ. Scandinavian Journal of Immunology. 44(3). 285–292. 22 indexed citations
16.
Bernhard, H., Gudrun Bernhard, Michael Heike, et al.. (1995). Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial. British Journal of Cancer. 71(1). 102–105. 33 indexed citations
17.
Jäger, Elke, H. Bernhard, Felix Theiss, et al.. (1995). Combination 5-fluorouracil (FU), folinic acid (FA), and α-interferon 2B in advanced gastric cancer: Results of a phase II trial. Annals of Oncology. 6(2). 153–156. 8 indexed citations
18.
Knuth, Alexander, H. Bernhard, Elke Jäger, et al.. (1994). Induction of tumour cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3. European Journal of Cancer. 30(8). 1103–1107. 5 indexed citations
19.
Bernhard, H., et al.. (1992). Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a.. PubMed. 19(2 Suppl 3). 204–7. 9 indexed citations
20.
Taheri, Syde A., et al.. (1991). Surgical Treatment of Primary Aortoduodenal Fistula. Annals of Vascular Surgery. 5(3). 265–270. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Clemens B. Caspar Breakdown of academic impact, for papers by Elizabeth K. Wansley Breakdown of academic impact, for papers by Satoko Matsueda Breakdown of academic impact, for papers by Laurence Lespagnard Breakdown of academic impact, for papers by A C Bloem Breakdown of academic impact, for papers by Anja Dankof Breakdown of academic impact, for papers by Marna Williams Breakdown of academic impact, for papers by G A Niehans Breakdown of academic impact, for papers by Baldev Vasir Breakdown of academic impact, for papers by Nacilla Haicheur
Rankless by CCL
2026